

**TEXAS HIV MEDICATION PROGRAM
MEDICAL CERTIFICATION FORM
Fax to (512) 989-4003**

(TO BE COMPLETED BY PHYSICIAN) **Texas HIV Medication Code (if known)** _____

The information requested is necessary to determine the patient's eligibility for program-supplied, HIV-related therapy as prescribed by you. All information requested will be kept strictly confidential by the Texas Department of State Health Services; personal identifying info is never released.

***** Both pages are required. *****

PATIENT INFORMATION

Full Name: _____

Mailing Address: _____ Apt#: _____

City: _____ State: _____ Zip: _____ Phone: _____

Date of Birth (mm/dd/yyyy): _____ Social Security Number: _____

Requested Pharmacy: _____

I hereby certify that this patient has been diagnosed with HIV, and I am reporting the following viral load and CD4 count:

Plasma RNA Viral Load: copies/ml	Test Date (mm/dd/yyyy):	Current CD4 Count:	Test Date (mm/dd/yyyy):
--	--------------------------------	---------------------------	--------------------------------

REQUIRED Is this patient new to any medications in this antiretroviral therapy regimen?
(check one) Yes ☐ No ☐

On the following page, mark the appropriate box to specify supply quantity for each medication prescribed. Medications marked n/a indicate the medication is not eligible for a 90-day supply. **Please refer to the [THMP Medication Formulary and Maximum Quantities Table](#) for available dosages and quantities of medications.** Providers should reserve prescribing a 90-day medication supply for people on stable medication regimens; medications that are new or have changed in dose for a patient are not eligible to be dispensed as 90-day supply.

Note:** Combivir, Descovy, Dovato, Evotaz, Epzicom, Prezcoibix, Truvada, and Juluca each count as 2 ARVs; Atripla, Complera, Odefsey, Trizivir, Triumeq, Biktarvy, and Delstrigo each count as 3 ARVs; Stribild, Symtuza, and Genvoya each count as 4 ARVs. ***HLA-B*5701 test result of negative is required for treatment-naïve patients starting medications that contain abacavir (Ziagen, Epzicom, Trizivir, or Triumeq).

I certify that this patient is being prescribed the medications selected on the attached page.

Physician Signature: _____ TX MD/DO License # _____

Printed Name of Physician: _____

Office Address: _____

Phone: _____ Fax: _____ Date: _____

*****NOTICE***** Changes in therapy after initial approval and/or recertification may be faxed to (512) 989-4003.

If this form is completed as part of an initial program application, it should be mailed to:
Texas HIV Medication Program, ATTN: MSJA - MC1873, PO Box 149347, Austin, TX 78714-9347

Patient Name: _____

Date of Birth: _____ Texas HIV Medication Code (if known): _____

Qty Prescribed (days)			Qty Prescribed (days)			Qty Prescribed (days)		
30 day			30 day			30 day		
☐ azithromycin	OR	☐ Clarithromycin				(choose one)		
☐ Dapsone	OR	☐ pentamidine	OR	☐ SMZ/TMP	(choose one)			
☐ acyclovir	OR	☐ famciclovir	OR	☐ Valacyclovir	(choose one)			
☐ Gynazole (butoconazole)	OR	☐ Monistat (tioconazole)	OR	☐ terconazole topical	(choose one)			
☐ fluconazole	OR	☐ itraconazole	OR	☐ Voriconazole	(choose one)			
☐ atovaquone (Mepron)			☐ clindamycin					
☐ clotrimazole troche			☐ Daraprim (pyrimethamine)					
☐ ethambutol			☐ Isoniazid					
☐ leucovorin calcium tablets			☐ megestrol acetate oral susp					
☐ nystatin oral susp			☐ Oravig (miconazole)					
☐ prednisone			☐ primaquine phosphate					
☐ rifampin			☐ rifabutin					
☐ sulfadiazine			☐ Valcyte (valganciclovir)					
ANTIRETROVIRALS RX: MONTHLY CLIENT LIMIT OF FOUR ANTIRETROVIRALS (ARVs)								
30	90 day		30	90 day		30	90 day	
☐	☐ Aptivus (TPV)		☐	☐ Atripla (ABC/FTC/TDF)		☐	☐ Biktarvy (BIC/FTC/TAF)	
☐	n/a Biktarvy pedi (BIC/FTC/TAF)		☐	☐ Combivir (AZT/3TC)		☐	☐ Complera (FTC/RPV/TDF)	
☐	☐ Delstrigo (DOR/3TC/TDF)		☐	☐ Descovy (FTC/TAF)		☐	☐ Dovato (DTG/3TC)	
☐	☐ Emtriva (FTC)		☐	☐ Epivir (3TC)		☐	☐ Epzicom (ABC/3TC)	
☐	☐ Evotaz (ATV/c)		☐	☐ Genvoya (c/EVG/FTC/TAF)		☐	☐ Intelence (ETR)	
☐	☐ Invirase (SQV)		☐	☐ Isentress (RAL)		☐	☐ Isentress pedi (RAL)	
☐	☐ Isentress HD (RAL)		☐	☐ Juluca (DTG/RPV)		☐	☐ Kaletra (LPV/r)	
☐	n/a Lamivudine/Tenofovir (3TC/TDF)		☐	☐ Lexiva (FPV)		☐	☐ Norvir (ritonavir)	
☐	☐ Odefsey (RPV/FTC/TAF)		☐	n/a Pifeltro (DOR)		☐	☐ Prezcobix (DRV/c)	
☐	☐ Prezista (DRV)		☐	☐ Reyataz (ATV)		☐	n/a Rukobia ER (fostemsavir)	
☐	☐ Selzentry (MVC)		☐	☐ Stribild (c/EVG/FTC/TDF)		☐	☐ Sustiva (EFV)	
☐	n/a Symfi (EFV/3TC/TDF)		☐	n/a Symtuza (c/DRV/FTC/TAF)		☐	☐ Tivicay (DTG)	
☐	n/a Tivicay pedi (DTG)		☐	☐ Triumeq (DTG/ABC3TC)		☐	☐ Trizivir (AZT/ABC/3TC)	
☐	☐ Truvada (FTC/TDF)		☐	☐ Viracept (NFV)		☐	☐ Viramune XR (NVP)	
☐	☐ Viread (TDF)		☐	☐ Ziagen (ABC)		☐	☐ Zidovudine (AZT)	
90 day			90 day			90 day		
☐	Amlodipine (5mg/#90)		☐	Atorvastatin (20mg/#90)		☐	Duloxetine (30mg/#90)	
☐	Gabapentin (300mg/#100)		☐	Hydrochlorothiazide (25mg/#100)		☐	Lisinopril (10mg/#100)	
☐	Metformin (500mg/#100)		☐	Metoprolol Tart (50mg/#100)		☐	Sertraline (50mg/#100)	
☐	Trazodone (100mg/#100)							